Empagliflozin and Cardiorenal Outcomes in Patients with Nonproteinuric Kidney Disease in the EMPA-REG OUTCOME Trial

Topics: 

Citation
Inzucchi SE et al. Diabetes Jun 2019; 68 (Supplement 1):248-OR.